PRMT5 Inhibition as a Potential Strategy for KRAS Mutant CRC: Downstream Mediators of the PRMT5-KRAS Crosstalk

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Colorectal cancer (CRC) is a major cause of cancer mortality globally.
• KRAS mutations occur in nearly 45% of CRC cases, leading to poorer prognosis and limited treatment options.
• Protein Arginine Methyltransferase 5 (PRMT5) is an epigenetic regulator and a potential therapeutic target, showing greater efficacy in KRAS-mutant CRC cells in prior studies.

Purpose of the Study:

• To identify downstream proteins mediating the interaction (crosstalk) between PRMT5 and KRAS in colorectal cancer.
• To investigate potential molecular mechanisms underlying the observed therapeutic differences between KRAS-mutant and wild-type CRC treated with PRMT5 inhibitors.

Main Methods:

• Literature review to identify candidate proteins.
• Protein-protein interaction analysis using the STRING database.
• Gene expression analysis and correlation studies using the GEPIA database on patient data.

Main Results:

• MYC, E2F1, and EIF4E were identified as critical candidate proteins involved in PRMT5-KRAS crosstalk.
• These candidate proteins interact with both PRMT5 and KRAS.
• MYC, E2F1, and EIF4E are overexpressed in CRC tumors and positively correlated with PRMT5 and KRAS gene expression in patient data.

Conclusions:

• The study provides novel insights into the PRMT5-KRAS crosstalk in colorectal cancer.
• MYC, E2F1, and EIF4E are proposed as key mediators of this interaction.
• These findings suggest potential novel therapeutic targets and combination strategies for KRAS-mutant CRC, warranting further experimental validation.